iAluRil is a medical device presented in a 50ml pre-filled syringe with a Luer-Lock adapter or iAluadapter® for easy use1.

iAluRil contains three active components: 800 mg/50 ml sodium hyaluronate (1.6%), and 1 g /50 ml sodium chondroitin sulfate (2%) and calcium chloride (0.87%).

iAluRil can be used for the treatment of:
– Interstitial cystitis
– Painful bladder syndrome
– Recurrent urinary tract infections
– Chemical-/radiation-induced cystitis (including BCG)

iAluRil® is the first intravesical GAG replacement therapy to combine one of the most abundant sulfated GAG molecules located on the bladder wall,2 chondroitin sulfate, with the most integral component of the GAG layer,3 hyaluronic acid. This combination is designed to facilitate faster and more effective restoration of the bladder epithelium.

Manufactured by IBSA FARMACEUTICI ITALIA SRL

1) iAluRil Prefill Patient Information. 2) Hurst RE et al. Functional and Structural Characteristics of the Glycosaminoglycans of the Bladder Luminal Surface. J Urol 1987; 138 (2): 433-437. 3) Stryer L. Biochemistry – 4th Edition. W.H. Freeman & Company; 1995. 4. Parsons CL et al. Abnormal Sensitivity to Intravesical Potassium in Interstitial Cystitis and Radiation Cystitis. Neurourol Urodyn 1994; 13(5): 515-520. 5. Damiano R et al. Prevention of Recurrent Urinary Tract Infections by Intravesical Administration of Hyaluronic Acid and Chondroitin Sulfate: a Placebo-Controlled Randomised Trial. Eur Urol 2011; 59(4): 645-651. 2011; 59(4): 645-651.

Essential Information
iAluRil Prefill for intravesical instillation Indication: To re-establish the glycosaminoglycan layers (GAGs) of the urothelial vesical tissue in cases in which their loss can cause frequent and recurring problems (such as, cystitis of varying etiology). Active Ingredients: Sodium hyaluronate (1.6%), Sodium chondroitin sulphate (2%) and Calcium chloride (0.87%). Please read the full patient information leaflet for further information and before administration. iAluRil should only be used after careful consultation with a trained healthcare professional.
If you are unsure about your diagnosis, please speak to your doctor or pharmacist

Always read the label

Revision reference – iAluRil_14_24.06.2021